Farmas USA

MNKD

Hedgie: This biotech stock is going to zero

http://www.cnbc.com/id/102658989

Estos van a saco

Pues hay lo tienes. Pero por ese motivo el suelo esta cerca y el rebote también

BELVIQ (ARNA)
BELVIQ continues to lead the market with 37.2% and 40.8% of the TRx, according to IMS and SH, respectively. BELVIQ TRx were up this week, 0.4% and 3.0% w/w, to 14,834 and 18,063 TRx, according to IMS and SH.

IMS:
NRx: down 0.2% (10,354 vs. 10,371; now 36.1% of the 4-drug total vs. 36.4% last week)
TRx: up 0.4% (14,834 vs. 14,769; now 37.2% of the 4-drug total vs. 37.5% last week)
Symphony Health:
NRx: up 2.6% (13,166 vs. 12,838; now 39.7% of the 4-drug total vs. 40.0% last week)
TRx: up 3.0% (18,063 vs. 17,544; now 40.8% of the 4-drug total vs. 41.1% last week)

Contrave (OREX)
Contrave TRx were up 1.7% and 4.2% w/w according to IMS and SH, respectively (13,154, up 1.7% (IMS), 15,766, up 4.2% (SH)) and the drug now has a ~33-36% market share. Contrave is in 2nd place in both datasets, having overtaken Qsymia in both IMS and SH TRx and closing in on Belviq.

IMS:
NRx: down 0.3% (9,925 vs. 9,950; now 34.6% of the 4-drug total vs. 35.0% last week)
TRx: up 1.7% (13,154 vs. 12,936; now 33.0% of the 4-drug total vs. 32.9% last week)
Symphony Health:
NRx: up 2.5% (12,264 vs. 11,960; now 37.0% of the 4-drug total vs. 37.3% last week)
TRx: up 4.2% (15,766 vs. 15,136; now 35.6% of the 4-drug total vs. 35.5% last week)

Qsymia (VVUS)
Qsymia TRx were up 0.5% and 2.2% according to IMS and SH, respectively, with its market share at 23%-29.3%. Qsymia scripts have remained flat over the last 20+ weeks of script data.

IMS:
NRx: up 0.7% (8,168 vs. 8,113; now 28.5% of the 4-drug total vs. 28.5% last week)
TRx: up 0.5% (11,675 vs. 11,612; now 29.3% of the 4-drug total vs. 29.5% last week)
Symphony Health:
NRx: up 2.3% (7,426 vs. 7,258; now 22.4% of the 4-drug total vs. 22.6% last week)
TRx: up 2.2% (10,183 vs. 9,968; now 23.0% of the 4-drug total vs. 23.4% last week)

Sigue muy estancada...Pensé que de cara al verano las ventas crecerían. Pero otra vez me he equivocado...

ARNA

Liberia libre del Ebola

http://www.elmundo.es/salud/2015/05/09/554ddcfc22601d37098b4574.html

Pues me alegro de la noticia. El Ebola es una infección latente que sigue y persigue y, que el que se haya abolido en Liberia tal infección,
En cualquier momento aparece.

Rebuscando la de cosas curiosas que se encuentra uno por la red un domingo por la mañana:

http://digitalcommons.pepperdine.edu/cgi/viewcontent.cgi?article=1053&context=scursas

o Stanley más jovencito, a ver si mejora el puesto

http://www.paxvax.com/sites/default/files/pdf/vaccinenation-2014-most-influential-people-in-vaccines.pdf

:)))

NVAX

Buenas,

el primer de los links lo lei hace bastante, se trato de una presentacion de unos estudiantes para un trabajo de universidad ...

El segundo link , muy interesante. :) Stan Erck  en posicion 19.

NVAX

TRANSCRIPCIONES REPORT FINANCIERO Q1 2015

Habra que echarle un vistazo a todo esto  ... 

Amarin's (AMRN) CEO John Thero on Q1 2015 Results - Earnings Call Transcript

AMRN

Novavax's (NVAX) CEO Stanley Erck on Q1 2015 Results - Earnings Call Transcript

NVAX